Gary Gibbons, MD, to Give Keynote Address at key Healthcare Product
Development Event, June 23-27 in San Diego
WASHINGTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/DIA2019?src=hash" target="_blank"gt;#DIA2019lt;/agt;–Amidst these incredibly exciting yet deeply challenging times in global
healthcare – from gene therapy, to access to treatment, to drug
development for rare diseases – 7,000 healthcare product development
professionals from over 50 countries will come together at DIA 2019, the
global annual meeting of DIA
(founded as the Drug Information Association), to tackle some of the
thorniest issues facing the world of health.
Running from June 23-27 in San Diego, CA, the
DIA 2019 Global Annual Meeting will feature a keynote speech from
Gary Gibbons, MD, Director of the National Heart, Lung, and Blood
Institute (NHLBI) at the National Institutes of Health (NIH). Dr.
Gibbon’s keynote speech, Advancing Discovery Science for Public
Health Impact, will address the value of “implementation science,”
which turns “discovery science” into practical means to improve peoples’
health, as well as the innovation of evidence-based initiatives in the
treatment of chronic disease.
Echoing a half century’s history of bringing together the voices of
patients, researchers and regulators in a neutral forum for meaningful
collaboration, DIA 2019 will catalyze conversations among a global
community of life sciences professionals at all levels and across all
disciplines, with a common goal of fostering innovation that will lead
to the development of safe and effective medical products and therapies
for patients. With more than 275 sessions and poster presentations
planned across 13 core interest areas, attendees will debate,
collaborate, and share – with no barriers – ideas about wide-ranging
topics that include the evolution of novel therapies, the pharmaceutical
research and development (R&D) landscape, and regulatory challenges to
action throughout the product development lifecycle.
“With regulatory changes, geo-political shifts, economic uncertainties –
and notably – the welcome and continued rise of patient-centered
involvement, the life sciences industry is tasked with ever-increasing
pressure to develop high-quality, innovative products,” said Barbara
Lopez Kunz, Global Chief Executive, DIA. “Providing a neutral,
multidisciplinary, cross-functional forum for learning and open
discussion, like DIA 2019, is essential for silo-busting and for moving
our field forward. That innovative drive aims to result in safe,
effective, quick – and, most importantly, accessible – healthcare for
patients.”
Combining traditional face-to-face educational sessions with eLearning
and other interactive experiences, DIA 2019 features themed tracks with
real-time scientific sessions focused on today’s trending topics,
including big data, medical affairs, regulatory policy and product
quality, clinical operations, patient engagement, and value and access.
The five-day conference will also feature a three-day expo with more
than 450 exhibiting companies from across the pharmaceutical,
biotechnology, data science, and medical device communities; DIAmond
Sessions, which feature in-depth conversations with U.S. Food and Drug
Administration (FDA), European Medicines Agency (EMA), and other health
authorities; and career development forums for students and emerging
professionals.
In addition to senior leaders from the biopharma industry, the FDA and
EMA, key representatives from many other global regulatory bodies and
research agencies will serve as session chairs and speakers, pressing
the group’s collective knowledge forward.
To learn more and register for DIA 2019, visit www.DIAglobal.org/DIA2019.
For live updates, follow and join the conversation on Twitter –
@DrugInfoAssn – using the hashtag #DIA2019.
About DIA
DIA (founded as the Drug Information Association) is a global
association that mobilizes life sciences professionals from across all
areas of expertise to engage with patients, peers, and thought leaders
in a neutral environment on the issues of today and the possibilities
for tomorrow. As a member-driven, volunteer organization, professionals
from more than 80 countries have affected healthcare outcomes, by
engaging with DIA through an unparalleled network, educational
offerings, and professional development opportunities.
DIA is based in Washington, DC (US) with regional offices representing
the Americas (Horsham, PA, US); Europe, the Middle East, and Africa,
(Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai,
India; and Tokyo, Japan).
For more information, visit DIAglobal.org
or connect with DIA on Twitter,
LinkedIn,
Facebook,
and Instagram.
Contacts
Michelle
Rovner, Associate Director, Marketing – Americas & Global Community
of Practice Leader
+1.215.442.6122
Michelle.Rovner@DIAglobal.org